SCHEMBL2457308

SCHEMBL2457308

Cc1ccc(S(=O)(=O)n2cccc2C=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 3/20 0.58
KDM4E B2RXH2 1/20 0.52
UBE2N P61088 1/20 0.52
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
PPME1 Q9Y570 6/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
APEH P13798 1/20 0.45
POLB P06746 2/20 0.44
HTT P42858 2/20 0.44
ALDH3A1 P30838 1/20 0.44
NOD1 Q9Y239 1/20 0.44
TRIM24 O15164 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
PKM P14618 2/20 0.42
GAA P10253 1/20 0.41
ACHE P22303 1/20 0.41
MMP2 P08253 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5776529 0.85 RAPGEF4 (0.56) RAPGEF4KDM4EUBE2NCA1CA2
SCHEMBL1616366 0.84 PPME1 (0.60) PPME1L3MBTL1APEHHTTTRIM24
SCHEMBL3968075 0.83 PPME1 (0.55) RAPGEF4PPME1APEHALDH3A1TRIM24
SCHEMBL3964674 0.83 PPME1 (0.58) RAPGEF4PPME1APEHALDH3A1PKM
SCHEMBL3964676 0.83 PPME1 (0.45) RAPGEF4PPME1APEHPOLBNOD1
SCHEMBL5247297 0.81 RAPGEF4 (0.60) RAPGEF4PPME1L3MBTL1APEHHTT
SCHEMBL3967048 0.80 PPME1 (0.43) RAPGEF4KDM4EUBE2NPPME1APEH
SCHEMBL3969689 0.80 PPME1 (0.64) CA1CA2PPME1L3MBTL1APEH
SCHEMBL4312461 0.79 RAPGEF4 (0.50) RAPGEF4KDM4EUBE2NCA1CA2
SCHEMBL4312459 0.79 RAPGEF4 (0.50) RAPGEF4KDM4EUBE2NCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140031562-A1 Method for Forming Allylic Alcohols THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOI (US) 2014-01-30 US claimed
WO-2010025366-A2 METHOD FOR FORMING ALLYLIC ALCOHOLS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2010-03-04 WO claimed
WO-2026099602-A1 DOMINO KNOEVENAGEL-INTRAMOLECULAR CYCLIZATION REACTIONS USING FIVE-MEMBERED AROMATIC HETEROCYCLES WITH ONE HETEROATOM AS A DIENE OR DIENOPHILE DEBRECENI EGYETEM (HU) 2026-05-15 WO disclosed
US-20260109699-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS IRBM S.P.A. (IT) 2026-04-23 US disclosed
EP-4594324-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS IRBM S.P.A. (IT) 2025-08-06 EP disclosed
CN-120129683-A Azole derivatives as SHP2 inhibitors IRBM股份公司 2025-06-10 CN disclosed
US-20250011330-A1 Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors LEIDOS BIOMEDICAL RESEARCH INC. 2025-01-09 US disclosed
US-20240239799-A1 (S)-1-(5-((PYRIDIN-3-YL)THIO)PYRAZIN-2-YL)-4'H,6'H-SPIRO[PIPERIDINE-4,5'-PYRROLO [1,2-B]PYRAZOL]-4'-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS SHP2 INHIBITORS FOR THE TREATMENT OF E.G. CANCER C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2024-07-18 US disclosed
WO-2024068976-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS IRBM S.P.A. (IT) 2024-04-04 WO disclosed
EP-4345101-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS IRBM S.P.A. (IT) 2024-04-03 EP disclosed
EP-4313983-A1 (S)-1-(5-((PYRIDIN-3-YL)THIO)PYRAZIN-2-YL)-4'H,6'H-SPIRO[PIPERIDINE-4,5'-PYRROLO [1,2-B]PYRAZOL]-4'-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS SHP2 INHIBITORS FOR THE TREATMENT OF E.G. CANCER C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) 2024-02-07 EP disclosed
US-7196078-B2 Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPOARTION (US) 2007-03-27 US disclosed
US-20070054906-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-08 US disclosed
US-20070054906-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-08 US disclosed
US-20070054925-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-08 US disclosed
US-20070054925-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-08 US disclosed
US-20070037824-A1 Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors SCHERING CORPORATION 2007-02-15 US disclosed
US-20070037824-A1 Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors SCHERING CORPORATION 2007-02-15 US disclosed
US-7161003-B1 Pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION (US) 2007-01-09 US disclosed
US-7161003-B1 Pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION (US) 2007-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054925-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors CDK2, CDK1, CDKN1A RAPGEF4 1907/4885KDM4E 731/4885UBE2N 1899/4885
US-20140031562-A1 Method for Forming Allylic Alcohols ADH1A, ADH1C, ADH5 RAPGEF4 1098/4885KDM4E 3939/4885UBE2N 1536/4885
US-20260109699-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS PTPN1, PTPN5, PTPN3 RAPGEF4 2043/4885KDM4E 1329/4885UBE2N 4561/4885
US-20250011330-A1 Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors TDP1, TDP2, TOP1 RAPGEF4 3058/4885KDM4E 1381/4885UBE2N 2993/4885
US-20070037824-A1 Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors CDK2, CDK5, CDKN1A RAPGEF4 3378/4885KDM4E 462/4885UBE2N 1999/4885
US-20070054906-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors CDK2, CDK1, CDKN1A RAPGEF4 1907/4885KDM4E 731/4885UBE2N 1899/4885
US-20240239799-A1 (S)-1-(5-((PYRIDIN-3-YL)THIO)PYRAZIN-2-YL)-4'H,6'H-SPIRO[PIPERIDINE-4,5'-PYRROLO [1,2-B]PYRAZOL]-4'-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS SHP2 INHIBITORS FOR THE TREATMENT OF E.G. CANCER PTPN1, PTPN5, PTPRJ RAPGEF4 909/4885KDM4E 906/4885UBE2N 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.